1. Home
  2. RCG vs NXL Comparison

RCG vs NXL Comparison

Compare RCG & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RCG

RENN Fund Inc

HOLD

Current Price

$2.74

Market Cap

18.1M

Sector

Finance

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.57

Market Cap

18.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCG
NXL
Founded
1994
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.1M
18.6M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
RCG
NXL
Price
$2.74
$0.57
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
5.9K
114.5K
Earning Date
01-01-0001
03-13-2026
Dividend Yield
0.98%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$156,931.00
Revenue This Year
N/A
$38.28
Revenue Next Year
N/A
$185.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.52
$0.54
52 Week High
$1.90
$3.87

Technical Indicators

Market Signals
Indicator
RCG
NXL
Relative Strength Index (RSI) 60.80 33.71
Support Level $2.60 $0.55
Resistance Level $2.75 $0.58
Average True Range (ATR) 0.09 0.04
MACD 0.01 0.00
Stochastic Oscillator 70.82 7.18

Price Performance

Historical Comparison
RCG
NXL

About RCG RENN Fund Inc

RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: